Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Ingber
Harvard Medical School, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Emulate, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Emulate, Inc. aims to commercialize technology comprised of "Organ-on-a-Chip" platforms to accelerate drug development, detect toxicities, and advance personal medicine. Dr. Ingber will study the organ-on-a-chip microdevices under the funded research identified above. The goal of the funded research identified above is to demonstrate that microengineered organ-on-a-chip microdevices can be used to define new molecular mechanisms of cellular mechanotransduction, which can then be leveraged to develop new therapeutics. Because Dr. Ingber's financial interest in Emulate, Inc. and the research identified above are related to the interests of the company, there is a potential for a possible conflict of interest between the performance of his research and teaching obligations at Harvard Medical School and his personal financial interests.
Mechanotransduction analysis in a microengineered lung-on-a-chip
Organ-on-Chip microfluidic devices lined by living human cells that mimic organ level structures and functions in vitro have the potential to transform how mechanistic research is carried out and how new therapies are developed. The goal of this application is to demonstrate the feasibility of using a microengineered `Lung-on-a-Chip' device to probe the molecular signaling mechanism induced by mechanical forces in the human lung, and to use this knowledge to develop new and improved inhibitors of pulmonary edema development.
Filed on May 18, 2015.
Tell us what you know about Donald Ingber's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Donald Ingber filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Ingber | Harvard University | Conflict of Interest | Emulate, Inc. | Value cannot be readily determined |
| Donald Ingber | Harvard University | Conflict of Interest | Emulate, Inc. | Value cannot be readily determined |
| Donald Ingber | Harvard Medical School | Conflict of Interest | Emulate, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.